Please assess the completion status of the following clinical trial:

Trial Title: 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Original diagnosis of neuroblastoma based on 1 of the following criteria:~  * Histopathology~ * Elevated urine catecholamines with typical tumor cells in the bone marrow~* Refractory or relapsed disease, meeting 1 of the following criteria:~  * Failure to respond to standard therapy (e.g., combination chemotherapy with or without radiotherapy and surgery)~ * Evidence of disease progression (i.e., any new lesion or an increase in size of \> 25% of a pre-existing lesion) at any time~* Evaluable disease by MIBG scan within 6 weeks of study entry~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* Negative pregnancy test~* Bilirubin \< 2 times normal~* AST/ALT ≤ 10 times normal~* Creatinine ≤ 2 mg/dL~* Absolute neutrophil count\* ≥ 750/mm\^3 (transfusion independent)~* Platelet count\* ≥ 50,000/mm\^3 (20,000/mm\^3 if stem cells are available and platelet transfusion independent)~* Hemoglobin\* ≥ 10 g/dL (transfusion allowed)~* No dyspnea at rest~* No exercise intolerance~* No oxygen requirement~* No clinically significant cardiac dysfunction~* No disease of any major organ system that would preclude study compliance~* No active infection that meets grade 3 or 4 toxicity criteria NOTE: \*Patients with granulocytopenia and/or thrombocytopenia due to tumor metastases to the bone marrow may be eligible at the discretion of the principal investigator~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Recovered from prior therapy~* At least 2 weeks since prior antitumor therapy~* At least 3 months since prior radiotherapy to any of the following fields:~  * Craniospinal~ * Total abdominal~ * Whole lung~ * Total body~* At least 1 day since prior cytokine therapy (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], interleukin-6, or epoetin alfa)~* Prior iodine I 131 metaiodobenzylguanidine allowed provided it was given more than 6 months ago AND patient has adequate hematopoietic stem cells available~* No concurrent hemodialysis

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).